BG Medicine (BG Medicine) Intangible Assets

: $0.08 Mil (As of Dec. 2015)

View and export this data going back to 2011. Start your Free Trial

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. BG Medicine's intangible assets for the quarter that ended in Dec. 2015 was $0.08 Mil.

BG Medicine Intangible Assets Historical Data

The historical data trend for BG Medicine's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Annual Data

Trend

Dec05

Dec06

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Intangible Assets

0.46

0.37

0.19

0.14

0.08

BG Medicine Quarterly Data
	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15
Intangible Assets																0.14	0.12	0.11	0.09	0.08

BG Medicine Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

BG Medicine (OTCPK:BGMD) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.

Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.

BG Medicine Intangible Assets Related Terms

Thank you for viewing the detailed overview of BG Medicine's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BG Medicine (BG Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Intangible Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 Wyman Street, Suite 300, Waltham, MA, USA, 02451

Website

http://www.bg-medicine.com

BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Executives

Jeffrey R Luber	director	100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos	director	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox	director	ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp	10 percent owner	ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr	10 percent owner
Flagship Ventures Fund 2007, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel	director	320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r.	director	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines